← Back to headlines
AbbVie's Deal with Apogee and Regenxbio's Gene Therapy Drug Drive Stock Movers
AbbVie's deal with Apogee and Regenxbio's progress on a gene therapy drug are highlighted as key factors influencing stock movements.
22 Jun, 15:12 — 22 Jun, 15:12
Sources
Showing 1 of 1 sources
